NSB 5.13% 3.7¢ neuroscientific biopharmaceuticals ltd

Ann: NSB - Glaucoma Study Update, page-3

  1. 5,109 Posts.
    lightbulb Created with Sketch. 953
    Another massively delayed study. There are always excuses and reasons but the company doesn't do right by shareholders to be so consistently inaccurate with their timelines.
 
watchlist Created with Sketch. Add NSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.